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Hypertension in Page (cellophane-wrapped) kidney is due to
interstitial nephritis.
Background. Cellophane wrapping of the kidneys (Page kid-
ney) induces perinephrits and hypertension, assumed to be due
to renal ischemia resulting from parenchymal compression by
the fibrous hull surrounding the kidneys. We investigated if
interstitial nephritis, rather than plasma angiotensin activity,
played a role in the development of hypertension in the Page
kidney model
Methods. We followed for 7 weeks rats with bilateral cello-
phane wrapping of the kidneys that received 20 mg/kg/day of
the immunosuppressive antiproliferative drug mycophenolate
mofetil (MMF) (two-kidney wrap/MMF) (N = 10) or vehicle
(two-kidney wrap) (N = 10), and sham-operated rats (N = 10).
Results. The two-kidney wrap group had progressive incre-
ment in blood pressure, inflammatory damage occupying 25%
to 50% of the renal tubulointerstitial region and increased num-
ber of angiotensin II–positive cells, angiotensin II content, and
oxidative stress in the kidney. MMF treatment prevented the
development of hypertension and renal inflammation without
modifying the perinephritic hull or the increment it induced
in the intrarenal pressure. The plasma levels of angiotensin II
were similar in the two-kidney wrap group, the two-kidney
wrap/MMF group and the sham-operated animals and un-
changed from baseline, despite the blood pressure increase in
the two-kidney wrap group.
Conclusion. Our results indicate that renal wrap hyperten-
sion is unrelated to plasma angiotensin II levels and related to
the inflammatory damage caused by the external compression
of the kidney.
In 1939, Page [1] described a model of hypertension
caused by perinephritis induced by cellophane wrapping
of the kidneys. He postulated that the fibrocollagenous
hull formed around the kidney as a reaction to the cello-
phane would compress the organ and stimulate the secre-
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tion of pressor substances, thus resembling the hyperten-
sion obtained by constriction of the renal arteries in the
classic Goldblatt experiments [2]. Subsequently, Groll-
man [3] presented a method of inducing hypertension
that he considered to be less complicated than constric-
tion of the renal artery and more reliable than the cel-
lophane wrapping of the kidneys, a figure eight ligature
encompassing both kidney poles. The hypertension in-
duced by cellophane wrapping and by figure eight wrap-
ping of one or both kidneys are generally assumed to have
the same pathophysiology. As stated in a recent review of
the clinical conditions capable of causing what is widely
known as “Page kidney,” external compression of the or-
gan causes renal hypoperfusion, ischemia, and activation
of the renin-angiotensin system (RAS) [4]
However, the participation of the circulating RAS in
pathogenesis of hypertension in the Page kidney has not
been confirmed and several findings suggest that other
mechanisms may play a more determinant role. First is the
observation that the reduction in dietary sodium prevents
and corrects hypertension in the renal wrap hypertension
[5, 6], in contrast to the lack of effects of sodium restric-
tion in the angiotensin-driven Goldbatt hypertension [7,
8]. Second are the observations of Haywood, Williams,
and Ball [6] who found that, in animals given a normal
sodium diet, angiotensin antagonists did not correct the
early nor the late hypertension in the one-kidney figure
eight wrap model. Finally, the studies of Hart et al [9]
recently reported that plasma angiotensin II levels are
unchanged during the progressive development of hyper-
tension and that volume load is the prevailing stimulus in
the early stages of renal wrap hypertension. In addition,
various clinical reports [10–13] indicate that relief of the
compression of the renal parenchyma may not correct the
hypertension, while removal of the kidney is usually suc-
cessful. The later observations suggested to Sterns et al
[13] that “parenchymal scarring” rather than parenchy-
mal compression may play a more significant role in the
persistence of hypertension.
The possibility that renal interstitial inflammation
could be playing a role in the hypertension caused by
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cellophane wrapping of the kidneys was attractive to us
because of previous investigations from our group have
explored the relationship between hypertension, renal
immune cell infiltration and oxidative stress (reviewed
in [14]). In these studies we have shown that strategies
leading to the reduction of the infiltration of lympho-
cytes and macrophages results in improvement in oxida-
tive stress and hypertension in acquired and in genetic
models of hypertension and, in particular, in the pre-
vention of salt-sensitive hypertension [15–17]. Therefore,
this investigation was designed to evaluate the role of
the renal interstitial inflammation in the pathogenesis of
the hypertension associated with the Page kidney model.
We found that blood pressure was unrelated to plasma
angiotensin II levels. Tubulointerstitial damage with ac-
cumulation of lymphocytes and macrophages, increased
angiotensin II–positive cells and angiotensin II content,
and augmented lipid peroxidation, reflecting oxidative
stress, were all demonstrated in the cellophane-wrapped
kidneys. Administration of the immunosuppressive anti-
inflammatory drug mycophenolate mofetil (MMF) did
not modify the formation of the fibrous capsule surround-
ing the kidney but reduced the inflammatory damage, an-
giotensin activity, and the oxidative stress of the kidney
and prevented the development of hypertension.
METHODS
Experimental design
Male Sprague-Dawley rats (Instituto Venezolano de
Investigaciones Cientı´ficas, Los Teques, Venezuela) were
used in the experiments. They were housed in institu-
tional animal facilities and had free access to standard
rat food (100 to 120 lEq sodium) (Protinal, Valencia,
Venezuela) and tap water. Animals were acclimatized
to the animal facilities for 1 week, conditioned to han-
dling and blood pressure determinations, and randomly
divided in two experimental groups and a control (sham-
operated) group. Experimental groups had bilateral cel-
lophane wrapping of the kidneys and received daily
20 mg/kg body weight of MMF (two-kidney/MMF group)
(N = 10) or vehicle (two-kidney wrap group) (N = 10) by
gastric gavage. MMF was given suspended in 500 lL of
water by vigorous agitation immediately before adminis-
tration as described in previous communications [14–18].
Rats were followed for 7 weeks after the cellophane
wrapping of the kidneys. Systolic blood pressure was
determined weekly by tail-cuff plethysmography (IITC,
Life Scientific Instruments, Woodland Hills, CA, USA) as
described in previous communications [14–18]. To rule
out potential gastrointestinal adverse effects of MMF
that would reduce dietary intake and thereby influence
blood pressure, food consumption was monitored and the
weight of the rats was determined at baseline, at 3 weeks,
and at the end of the experiment (7 weeks) when ani-
mals were euthanized. At the time of sacrifice, intrarenal
pressure was determined, the fibrous hull surrounding
each kidney were removed and weighed and the kidneys
were then harvested for histologic and immunohistologic
studies and determination of angiotensin II and malon-
dialdehyde (MDA) content.
Plasma creatinine and 24-hour urinary protein excre-
tion were determined at baseline, at 4 weeks and 7 weeks
after kidney wrapping.
Surgical procedures
Under general anesthesia (diazepam/ketamine) kid-
neys were exposed by a midline laparotomy and included
in cellophane bags made from cellophane sheets, as de-
scribed by Page [1] taking care that renal pelvis, ureter,
and the vascular pedicle were completely free and undis-
turbed. Sham-operated animals only had manipulation
of the kidneys.
Intrarenal pressure determinations
Hydrostatic pressure of the kidneys inside the fibrous
hull caused by the cellophane wrap was determined by
direct intrarenal fine-needle manometry at the time of
sacrifice in five rats from each group. The method has
been used by others [19], as well as us [20], to estimate
intrarenal pressure during acute rejection in transplanted
kidneys. Briefly, a 23 gauge scalp vein set with a three-way
connection to a column of sterile 0.9% saline solution was
inserted inside the renal parenchyma prior to the removal
of the cellophane-induced fibrous hull. Immediately af-
ter insertion of the needle and assuring free communica-
tion with the saline column, measurements were taken.
The height above the kidney at which the saline column
stopped flowing toward the kidney was considered rep-
resentative of the intrarenal pressure in centimeters of
H2O. There were no significant differences in paired mea-
surements in right and left wrapped kidneys. Because it
was technically easier, we chose to evaluate intrarenal
pressure in the left kidney. Three determinations in sepa-
rate areas of the kidney (after testing that needle and the
system were patent in each instance) were made in each
animal and their average was considered to represent the
intrarenal pressure.
Plasma and renal angiotensin II
Determination of plasma angiotensin were done in
2 mL blood samples obtained at baseline, at 3 weeks,
and at 7 weeks (sacrifice) after kidney wrapping. Plasma
was collected in chilled tubes containing an inhibitor mix-
ture [50 lL 0.3 mol/L ethylenediaminetetraacetic acid
(EDTA) and 2.5 lL 0.5 mol/L 1,10-phenatroline per
mL] and determinations of plasma angiotensin II were
done by enzyme-linked competitive immunoassay using
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commercially available kits (Peninsula Laboratories, Inc.,
San Carlos, CA, USA) after extraction in C18 Sep
columns following the procedure recommended by the
manufacturer. The minimal detectable concentration is
0.03 ng/mL assay tube and the intra- and interassay vari-
ations are 5 ± 2% and 12 ± 3%, respectively.
Renal angiotensin II was determined following the
guidelines of Durvasula et al [21] in five kidneys of
each group that were removed after perfusion with
cold saline solution. Briefly, the renal cortex was im-
mediately excised, cut in small pieces, and placed in
a solution at 2◦C containing 20 mmol Tris HCl (pH
7.40), 10 mmol//L of EDTA, 5 mmol/L, ethyleneglycolte-
traacetic acid (EGTA), and protease inhibitor cocktail
one tablet per 10 mL (Roche, Molecular Biochemicals,
Indianapolis, IN, USA). Tissues were homogenized by
pulse sonication in ice and then centrifuged at 16,000 × g
for 15 minutes at a temperature of 2◦C [21]. Supernatants
were collected in cold polypropylene tubes and placed
at −20◦C until the determination of angiotensin II was
done. Angiotensin II was determined by enzyme-linked
competitive immunoabsorbent assay after extraction in
C18 Sep columns (Peninsula Laboratories, Inc.) using a
10 point standard curve (0 to 10 ng/mL assay tube). Intra-
and interassay variation were 10 ± 8% and 28 ± 5%, re-
spectively. Results are expressed in fmol/g of renal cortex.
Recovery of angiotensin II added prior to extraction was
77 ± 7.5% for blood and 84 ± 12% on renal cortical ho-
mogenates.
Renal MDA and glutathione (GSH) content
Determinations of MDA and GSH content were done
in one of the kidneys harvested at the time of sacrifice by
the method of Ohkawa, Ohishi, and Yagi [22] and Beut-
ler, Duron, and Milkus [23], respectively. MDA and GSH
were measured in supernatants of kidney slices placed in a
cold mixture of 100 mmol/L KCl and 0.003 mol/L EDTA,
homogenized and centrifuged at 600g. Specific details of
this methodology in our laboratories have been published
previously [24].
Histology and immunohistology
Histology was studied by light microscopy in paraffin-
embedded kidney sections fixed in Methyl Carnoy and
stained with periodic acid-Schiff (PAS), hematoxylin
and eosin, and trichromic stains. Glomerulosclerosis was
graded and scored as described by Raij, Azar, and Keane
[25] and detailed previously [14–17] Tubulointerstitial
damage was scored using a 0 to 5 scale depending on
the extent of areas with tubular dilatation, interstitial
infiltration and fibrosis (0, no changes; grade 1, <10%;
grade 2, 10% to 25%; grade 3, 25% to 50%; grade 4,
50% to 75%; and grade 5, 75% to 100%), determined in
successive fields examined in the entire cortical and jux-
tamedullary areas suited for evaluation of each biopsy,
using computer assisted image analysis (Olympus BX51
System Microscope and DP70 microscope Digital cam-
era, with software of Sigma Pro, Leesburgh, VA, USA).
Avidin-biotin-peroxidase methodology [26] was used
to study to identify lymphocytes (CD5-positive cells),
macrophages (ED1-positive cells), and angiotensin II–
positive cells.
Glomeruli and tubulointerstitial regions were evalu-
ated separately and results were expressed as positive
cells per glomerular cross section (gcs) and positive cells
per mm2, respectively. All studies were done in a blinded
fashion.
Antisera
Anti-CD5 and anti-ED1 monoclonal antibodies
(Biosource, Camarillo, CA, USA) were used to identify
lymphocytes and macrophages, respectively. Rabbit anti-
human angiotensin II antiserum with cross-reactivity to
rat angiotensin II (Peninsula Laboratories, Inc.) was used
to identify angiotensin II–positive cells and specificity of
the staining was tested by preincubating the antibody with
human angiotensin II as described in a previous commu-
nication [27]. Secondary biotin-conjugated affinity-pure
antibodies with minimal reactivity to rat serum proteins
were purchased from Accurate Chemical and Scientific
Co. (Westbury, NY, USA). Nonrelevant antibodies were
used for negative control studies.
Statistical analysis
Results were analyzed with analysis of variance us-
ing a commercially available statistical package (Instat,
GraphPad R, San Diego, CA, USA) and significant differ-
ences defined with Tukey post tests. Results are expressed
as mean ± SD and differences are considered significant
when P < 0.05.
RESULTS
Renal function and body weight
There were no significant changes in plasma creatinine
concentration or in urinary protein excretion. Plasma cre-
atinine (mg/dL) was similar at baseline (two-kidney wrap
group = 0.43 ± 0.12 and two-kidney wrap/MMF group
= 0.35 ± 0.12), at 4 weeks (two-kidney wrap group =
0.41 ± 0.16 and two-kidney wrap/MMF group = 0.35 ±
0.12), and at the end of the experiments (two-kidney wrap
group = 0.42 ± 0.15 and two-kidney wrap/MMF group =
0.40 ± 0.15). Proteinuria (mg/24 hours) was also simi-
lar at baseline (two-kidney wrap group = 6.0 ± 2.3 and
two-kidney wrap/MMF group = 3.5 ± 1.0), at 4 weeks
(two-kidney wrap group = 7.2 ± 5.4 and two-kidney
wrap/MMF group = 2.6 ± 1.7), and at the end of the
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Fig. 1. Systolic blood pressure (SBP) changes after kidney cellophane
wrapping. The mycophenolate mofetil (MMF)-treated group (2K-wrap
+ MMF) () maintains a blood pressure at similar levels than the sham-
operated group (), in contrast with the progressive elevation of the
blood pressure in the untreated kidney wrap group (2K-wrap) (). Val-
ues are mean ± SD. ∗∗∗P < 0.001 vs. the rest.
experiment (two-kidney wrap group = 4.3 ± 3.3 and two-
kidney wrap/MMF group = 2.1 ± 1.8).
There was a significant (P < 0.01) increase in weight
in the sham-operated control group at the end of the ex-
periment (445 ± 55 g) with respect to the initial weight
(378 ± 35 g). There no significant differences in the weight
of the MMF-treated (two-kidney wrap/MMF) and un-
treated (two-kidney wrap) groups with kidney wrapping
(initial weight two-kidney wrap group = 381 ± 35.3 g and
two-kidney wrap/MMF group = 399 ± 28.7 g; weight at
the end of the experiment two-kidney group = 401 ±
67.3 g and two-kidney/MMF group = 403 ± 89.7 g).
Blood pressure
Blood pressure findings are shown in Figure 1. The two-
kidney weight group experienced progressive increments
in systolic blood pressure beginning 1 week after cello-
phane wrapping of the kidneys and reached values of
157 ± 6.18 mm Hg after 7 weeks. In contrast, the blood
pressure in the two-kidney wrap/MMF group remained
at baseline values as did in the sham-operated control
group.
Intrarenal pressure and the fibrous hull surrounding
the kidney
Intrarenal pressure at the end of the experiment was
7.6 ± 4.0 cm H2O in the sham-operated group and was
significantly (P < 0.01) elevated in the two-kidney wrap
group (22.3 ± 5.15) and in the two-kidney wrap/MMF
group (25.6 ± 5.49). The difference in intrarenal pressure
between the untreated (two-kidney wrap) and the MMF
treated (two-kidney wrap/MMF) kidney-wrapped groups
was not significant (Fig. 2A)
The weight of the fibrous capsule surrounding the kid-
ney was comparable in the right and the left kidneys and
there were no significant differences between the MMF-
treated and the untreated experimental groups (Fig. 2B).
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Fig. 2. Reactions to cellophane wrapping. (A) Intrarenal pressure
measurements after 7 weeks of cellophane wrapping of the kidneys.
Values correspond to the left kidney that was chosen for technical ex-
pediency (see text). ∗∗P < 0.01 vs. the others. (B) Dry weight of the
capsule formed around the kidney in reaction to cellophane wrapping.
Abbreviations are: RK, right kidney hull; LK, left kidney hull; 2KW,
untreated two-kidney wrap; 2KW.MMF, two-kidney wrap treated with
mycophenolate mofetil (MMF). Values are mean ± SD. Weight differ-
ences between hulls in left and right kidneys and between treated and
untreated groups are not significant.
Histologic examination of the fibrous hull did not re-
veal differences between the MMF-treated and untreated
groups.
Plasma and renal angiotensin II
The plasma angiotensin II levels determined at three
different time intervals in the experiment were not sig-
nificantly different in the experimental groups and the
control group (Fig. 3A).
The angiotensin II content in the renal cortex is shown
in Figure 3B. As shown, the two-kidney wrap group had
increased angiotensin II while the two-kidney wrap/MMF
group had values that were essentially similar to those in
the sham-operated kidneys.
The plasma angiotensin II levels in the two-kidney
wrap group were stable, in contrast with the progres-
sive hypertension developed by these rats, as shown in
Figure 4. The changes in plasma angiotensin II observed
Vanegas et al: Renal inflammation in Page kidney hypertension 1165
** *
1200
1000
800
600
400
200
0
R
en
al
 a
ng
io
te
ns
in
 ll,
 fm
ol
/g
Sham 2KW 2KW.MMF
B
140
120
100
80
60
40
20
0
Pl
as
m
a 
Al
l, 
fm
ol
/m
L
Basal 3-4 week 7 week
2KW
2KW.MMF
Sham
A
Fig. 3. Plasma (A) and renal (B) angiotensin II (AII) levels in ex-
perimental groups. No significant differences exist between the values
in the untreated rats with kidney wrap (2KW group) (), the group
treated with mycofenolate mofetil (MMF) (2KW.MMF group) () and
the sham-operated rats (), at any of the time intervals tested. Values
are mean ± SD. (B) Angiotensin II content per g of renal cortex. Cel-
lophane wrapped kidneys have increased angiotensin II that is reduced
to normal levels by MMF treatment. Bars representing the groups as in
(A). Values are mean ± SD. ∗P < 0.05; ∗∗P < 0.01.
during the study were unrelated to the changes observed
in blood pressure levels (data not shown).
Light microscopy
Glomeruli were in general normal or presented mesan-
gial expansion Glomerulosclerosis (score 0 to 400 range in
the method used) was rare and similar in the two-kidney
wrap group (6.8 ± 5.56) and the two-kidney wrap/MMF
group (4.44 ± 5.83).
Tubulointerstitial damage induced by cellophane per-
inephritis was prominent in the two-kidney wrap group,
occupying 25% to 70% of the renal cortex (3.0 ± 0.77
score). Damage consisted of extense areas of intense cel-
lular infiltration, with focal areas of fibrosis and occa-
sional dilated tubules. The tubulointerstitial findings in
the two-kidney wrap/MMF group, when present, com-
prised less than 10% of tubulointerstitial areas (1.0 ±
0.51 score) (P < 0.001 vs. the two-kidney wrap group)
(Fig. 5A and B).
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Fig. 4. Plasma angiotensin II (AII) levels in relation to the progressive
increment in the systolic blood pressure in kidney wrap hypertension
(two-kidney wrap group). Values of plasma angiotensin II remain steady
as the hypertension develops and becomes increasingly severe. Data are
mean ± SD.
Infiltrating cells
The number of intraglomerular lymphocytes and
macrophages was not increased in the experimental
groups (<0.7 positive cells/gcs). In contrast, there was
significant tubulointerstitial infiltration of lymphocytes
(CD5-positive cells) and macrophages (ED1-positive
cells) in the two-kidney wrap group. MMF treatment
reduced tubulointerstitial immune cell accumulation
(Figs. 5C and D and 6). Angiotensin II–positive cells
were generally absent in the tubulointerstitial areas of
sham-operated rats; however, they were present in the
two-kidney wrap group and MMF treatment reduced
their numbers (Fig. 7A). The angiotensin II–positive cells
were both tubular cells and infiltrating cells (Fig. 7B) and
double-staining studies (not shown) demonstrated that
20% to 30% of the infiltrating macrophages stained pos-
itive for angiotensin II.
Renal MDA and GSH content
Renal MDA content was increased in the two-kidney
wrap group and reduced to normal levels by MMF treat-
ment (Fig. 8). The renal GSH content was comparable in
the two-kidney wrap group (7.63 ± 2.82 nmol/mg protein)
and the two-kidney/MMF group (5.97 ± 2.1).
DISCUSSION
The present studies were done to gain insight on the
pathogenesis of hypertension associated with the cello-
phane kidney wrap model of perinephritis. As initially
postulated by Page in 1939 [1], the presently accepted
views implicate a mechanism similar to the Goldblatt
model of renal artery constriction. In the kidney wrap
model, renal ischemia would be the consequence of the
compression exerted by the perinephritic hull formed in
reaction to the cellophane wrapping [4]. The central find-
ings of the present work are (1) the demonstration that
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DC
Fig. 5. Intense tubulointerstitial inflammatory infiltrate surrounding glomeruli showing mesangial expansion in the cellophane wrapped untreated
rats and (A) contrasts with the normal appearance of the biopsy of a mycophenolate mofetil (MMF)-treated rat (B) [periodic acid-Schiff (PAS)
staining]. Tubulointerstitial lymphocyte infiltration (CD5-positive cells) (immunoperoxidase staining) in the biopsy of an untreated rat (C) is reduced
by MMF treatment (D).
the hypertension is unrelated to the plasma angiotensin II
levels, in agreement with the work of Hart et al [9]; (2) that
cellophane perinephritis results in significant tubuloint-
erstitial inflammatory damage; and (3) that suppression
of the immune cell infiltration prevents tubulointersti-
tial damage and hypertension in the Page kidney model,
without modification of the mechanical effects of the per-
inephritic fibrous hull surrounding the kidney.
We selected male rats for this study because female
rats are partially protected against renal wrap hyperten-
sion [28] and choose the cellophane, rather than the figure
eight, kidney wrap model because cellophane wrapping
results in a well-defined fibrous hull that can be removed
and weighted. In addition, the perinephritic hull result-
ing from cellophane wrapping has more resemblance to
the clinical conditions known as Page kidney (see later).
We favored the two-kidney two-wrap model because this
model is more reliable in inducing hypertension than the
one-kidney wrap model, if the later is not associated with
contralateral nephrectomy [1], and we wanted to avoid
superimposed tubulointerstitial inflammation resulting
from renal mass reduction.
The intrarenal pressure measured in the sham-
operated group in the present study is in the normal
range of interstitial hydrostatic pressure reported in stud-
ies of Khairibi [29] and Tang, Yu, and Khraibi [30]. The
fibrous hull that surrounded the cellophane wrapped kid-
neys increased the intrarenal pressure about threefold
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Fig. 6. Effects of kidney wrap. (A) Kidney wrap hypertension (2KW
group) () is associated with lymphocyte (CD5-positive cells) infiltra-
tion in tubulointerstitial areas. Mycophenolate mofetil (MMF) treat-
ment (2KW.MMF group) ( ) reduces the lymphocyte infiltration. (B)
Macrophage (ED1-positive cells) infiltration in tubulointerstitial areas
is a feature of kidney wrap hypertension (2KW group) () and is reduced
by MMF treatment (2KW.MMF) ( ). The data in the sham-operated
group are shown (). Values are mean ± SD. ∗∗P < 0.01; ∗∗∗P < 0.001.
at the end of 7 weeks. These findings are in agreement
with the studies on Denton and Anderson [31], who re-
ported that renal venous wedge pressure was elevated
in the renal wrap model in rabbits. However, it is un-
likely that intrarenal pressure per se could be the cause
of hypertension since the treatment with MMF did not
modify intrarenal pressure or the size of the fibrous hull
surrounding the kidney (Fig. 2) and, nevertheless, ame-
liorated tubulointerstitial inflammation, preserved renal
integrity, and prevented the development of hypertension
in the two-kidney wrap/MMF group (Fig. 1). In contrast
with the findings of others [9], tubulointerstitial injury
was prominent. It may be noted that tubulointerstitial
inflammation is a more conspicuous characteristic of in-
creased intrarenal pressure than is glomerular damage,
since glomeruli were for the most part intact, even when
immersed in areas of significant tubulointerstitial dam-
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Fig. 7. Increased numbers of angiotensin II (AII)-positive cells in
tubulointerstitial areas in kidney wrap model. (A) Hypertension
(2KW group) (). Mycofenolate mofetil (MMF) treatment (2KW.MMF
group) ( ) reduces the number of angiotensin II–positive cells. Value in
sham-operated rats is shown (). Values are mean ± SD. ∗P < 0.05, ∗∗∗P
< 0.001. (B) Angiotensin II–positive cells in tubulointerstitial areas in
the kidney wrap model (immunoperoxidase technique).
age in the two-kidney wrap group (Fig. 5A). Similar pre-
ponderance of tubulointerstitial inflammatory injury is a
characteristic of other models of salt-driven hypertension
[14–18].
It is unlikely that systemic angiotensin activity plays a
significant role in the development of hypertension since
angiotensin II plasma levels were comparable in all exper-
imental groups (Fig. 3). Furthermore, in the two-kidney
wrap group plasma angiotensin II levels remained steady
despite the progressive increment of the blood pressure
(Fig. 4). However, stable levels of plasma angiotensin
II are physiologically inappropriate in the face of hy-
pertension [32] and prolonged activation of intrarenal
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Fig. 8. Renal malondialdehyde (MDA) content is increased in renal
wrap. Hypertension (2KW group) (). Mycophenolate mofetil (MMF)
treatment (2KW.MMF group) ( ) reduces MDA content to levels com-
parable to those found in the sham-operated group (). Data are mean
± SD. ∗P < 0.05.
angiotensin II, as demonstrated in Figure 3B, may have
resulted in a down-regulation of extrarenal angiotensin
II production.
Our results are in agreement with the previously men-
tioned studies of Hart et al [9] who also found unchanged
levels of plasma angiotensin II in this model as well as
with the observation that angiotensin-converting enzyme
(ACE) antagonists failed to correct hypertension in rats
renal wrap model [6]. In contrast, Denton and Anderson
[31] and Siragy and Carey [11] found early increments
in plasma renin activity and plasma angiotensin II and
that administration of losartan during this period acutely
lowers the blood pressure [11]. The same research group
[33] found that 3 days after surgery there was a down-
regulation of the angiotensin II type 1a receptor expres-
sion suggesting increased levels of the ligand. It is possible
that when we first tested plasma angiotensin II, the third
week after surgery, the levels may have already returned
to normal, as is the case in the two-kidney one-clip hy-
pertension, in which the plasma angiotensin II levels are
increased at day 7 and return to normal by day 25 after
surgery [34]. However, in two-kidney one-clip hyperten-
sion, blood pressure increases soon after surgery, while in
the cellophane wrap model hypertension develops pro-
gressively, as initially reported by Page [1] and confirmed
in the present studies (Fig. 1). Therefore, if plasma lev-
els of angiotensin II were increased in the first week or
two after surgery they would have been associated with
relatively minor hypertensive effects.
In our experiments, hypertension was prevented by
MMF treatment that controlled renal inflammation and
intrarenal angiotensin II activity and oxidative stress.
These findings, taken in context with the progressive,
rather than sudden increment in blood pressure, and with
the findings previously mentioned that a low-salt diet pre-
vents hypertension in the renal wrap model [5, 6] and
that volume load is the primary drive for hypertension
[9], strongly suggest that renal sodium retention plays a
determinant role in the pathogenesis of hypertension in
the Page kidney model.
In contrast to experimental observations, the patients
with Page kidney usually have high plasma renin activity
in the renal vein of the affected kidney. We did not mea-
sure renal vein plasma renin activity but it appears un-
likely that it would have been different in the two-kidney
wrap group and in the two-kidney wrap/MMF group
since, as mentioned before, the mechanical compression
of the kidney and the systemic angiotensin II levels were
similar. Most of the patients with Page kidney–like con-
ditions in the literature have subcapsular hematomas or
cysts (reviewed in [4, 35]) and, more rarely, perinephritis
[36]. Therefore, our findings may not be directly extrap-
olated to those patients. However, it may be noted that
seldom is the relief of the compression sufficient to cor-
rect the hypertension and nephrectomy is usually needed
for this purpose [13]. An additional observation that un-
derscores the physiopathologic differences between re-
nal artery stenosis and the Page kidney is the finding that
captopril renography, a test for renal artery stenosis, is
negative in patients with Page kidney [37].
We cannot answer from our study when the tubuloint-
erstitial immune cell infiltration starts in this model but its
pathogenetic relevance is strongly suggested by the find-
ing that its suppression with MMF treatment prevents
hypertension. While MMF has a variety of effects on res-
ident kidney cells (reviewed in [38]) that may contribute
to its beneficial effects, the results of the present inves-
tigation are consistent with previous studies in a variety
of experimental models in which reduction of the inflam-
matory infiltrate reduces oxidative stress and improves or
prevents hypertension (reviewed in [14]) even in experi-
mental models that do not present significant interstitial
fibrosis or significant nephron loss [15, 18]. The adminis-
tration of MMF was well tolerated. Experimental groups
that had cellophane wrapping of the kidneys failed to gain
weight significantly but the weight was similar in the un-
treated hypertensive two-kidney wrap group and in the
normotensive two-kidney wrap/MMF group. Therefore
it is unlikely that dietary factors would be responsible
for the prevention of hypertension in the MMF-treated
group.
Increased numbers of angiotensin II expressing cells in
tubulointerstitial areas were observed in association with
interstitial nephritis in the two-kidney wrap group. As
in previous reports [14–18], the angiotensin II–positive
cells were both proximal tubular cells and infiltrating
cells and their numbers were reduced by MMF treatment
(Fig. 7). These findings are strengthened by the demon-
stration that the angiotensin content in the renal cortex
was increased by renal cellophane wrapping and reduced
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to levels similar to those found in sham-operated rats by
MMF treatment (Fig. 3B). Since the intrarenal pressure
and perinephritic hull resulting from cellophane wrap-
ping was not modified by MMF (Fig. 2), it is likely that
the reduction in intrarenal angiotensin II was also related
to the improvement in the interstitial inflammation.
The reduction of renal MDA content observed with
MMF treatment (Fig. 8) is not unexpected since lipid
peroxidation resulting from unchecked generation of
reactive oxygen species would be likely reduced as a con-
sequence of improvement of interstitial inflammation, as
has been reported in previous studies [15–18].
The mechanisms involved in the development and
maintenance of hypertension associated with renal in-
terstitial inflammation have been recently reviewed [14]
and relate to the interplay of angiotensin II activity and
unchecked generation of reactive oxygen species that re-
sult in a tendency to sodium retention by the kidney. The
present studies did not evaluate sodium balance but it is
reasonable to assume that the demonstrated increment in
renal angiotensin activity and oxidative stress would im-
pose a reduction in urinary sodium excretion until a new
balance is achieved at a higher level of blood pressure.
Investigations by several groups have shown that that
renal wrap hypertension is temporarily reduced by ab-
lation of the paraventricular nucleus [39], sympathetic
blockade [40], and V1 receptor blockade [41]. Particu-
larly relevant to the present work are the investigations
of Haywood, Williams, and Ball [6], Hinojosa-Laborde,
Guerra, and Haywood [40], and Hinojosa and Haywood
[41] who have shown that hypertension is salt sensitive in
the renal wrap model and those of Hart et al [9] who de-
termined that volume load, rather than humoral factors,
is the prevailing condition in the early phase of hyperten-
sion. Our results offer a potential explanation for their
findings because, as indicated earlier, salt retention is the
expected result of the combined effects of interstitial in-
flammation and oxidative stress [14]. These factors, driv-
ing a tendency to sodium retention, may be responsible,
at least in part, for the lack of a natriuretic response to
atrial natriuretic peptide in renal wrap hypertension [42].
CONCLUSION
Our results show that the progressive hypertension in-
duced by cellophane wrapping of the kidneys is unrelated
to plasma angiotensin II levels and to the mechanical ef-
fects of compression caused by the perinephritis. While
unchanged plasma angiotensin II levels maybe physiolog-
ically inappropriate, interstitial inflammation and tubu-
lar damage of the wrapped kidneys, likely driven by
increased intrarenal angiotensin activity and oxidative
stress, appear to play a determining role since correction
of these features with MMF administration prevents the
increment in blood pressure that is characteristic of this
model.
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